[go: up one dir, main page]

TNSN92007A1 - Nouveaux steroides - Google Patents

Nouveaux steroides

Info

Publication number
TNSN92007A1
TNSN92007A1 TNTNSN92007A TNSN92007A TNSN92007A1 TN SN92007 A1 TNSN92007 A1 TN SN92007A1 TN TNSN92007 A TNTNSN92007 A TN TNSN92007A TN SN92007 A TNSN92007 A TN SN92007A TN SN92007 A1 TNSN92007 A1 TN SN92007A1
Authority
TN
Tunisia
Prior art keywords
compounds
new steroids
hydrogen atom
steroids
new
Prior art date
Application number
TNTNSN92007A
Other languages
English (en)
Inventor
Hakan Andersson Paul
Ingemar Axelsson Bengt
Lennart Brattsand Ralph
Bror Thalen Arne
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN92007A1 publication Critical patent/TNSN92007A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DES COMPOSES DE FORMULE GENERALE (I) SOUS LA FORME D'UN EPIMERE 22R ET 22S, DANS LESQUELS X1 ET X2 SONT LES MEMES OU DIFFERENTS, ET CHACUN REPRESENTE UN ATOME D'HYDROGENE OU UN ATOME DE FLUOR, SOUS RESERVE QUE X1 ET X2 NE SOIENT PAS SIMULTANEMENT UN ATOME D'HYDROGENE ; DES PROCEDES EN VUE DE LEUR PREPARATION, DES PREPARATIONS PHARMACEUTIQUES LES CONTENANT, ET L'EMPLOI DES COMPOSES DANS LE TRAITEMENT D'AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES
TNTNSN92007A 1991-02-04 1992-02-04 Nouveaux steroides TNSN92007A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100341A SE9100341D0 (sv) 1991-02-04 1991-02-04 Novel steroids

Publications (1)

Publication Number Publication Date
TNSN92007A1 true TNSN92007A1 (fr) 1993-06-08

Family

ID=20381806

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN92007A TNSN92007A1 (fr) 1991-02-04 1992-02-04 Nouveaux steroides

Country Status (40)

Country Link
US (2) US5674861A (fr)
EP (1) EP0570454B1 (fr)
JP (1) JPH06505232A (fr)
KR (1) KR100216720B1 (fr)
CN (3) CN1034868C (fr)
AP (1) AP366A (fr)
AT (1) ATE178611T1 (fr)
BG (1) BG62211B1 (fr)
CA (1) CA2103924A1 (fr)
CZ (1) CZ281685B6 (fr)
DE (1) DE69228870T2 (fr)
DK (1) DK0570454T3 (fr)
DZ (1) DZ1553A1 (fr)
EE (1) EE03111B1 (fr)
ES (1) ES2133315T3 (fr)
FI (1) FI933450A0 (fr)
GR (1) GR3030657T3 (fr)
HK (1) HK1010733A1 (fr)
HU (1) HU218275B (fr)
IE (1) IE920166A1 (fr)
IL (1) IL100532A (fr)
IS (1) IS1601B (fr)
MA (1) MA22406A1 (fr)
MX (1) MX9200324A (fr)
NO (1) NO304073B1 (fr)
NZ (1) NZ241210A (fr)
PH (1) PH31284A (fr)
PL (1) PL170000B1 (fr)
PT (1) PT100086B (fr)
RO (1) RO111195B1 (fr)
RU (1) RU2111212C1 (fr)
SE (1) SE9100341D0 (fr)
SG (1) SG52557A1 (fr)
SI (1) SI9210065B (fr)
SK (1) SK281801B6 (fr)
TN (1) TNSN92007A1 (fr)
UA (1) UA41267C2 (fr)
WO (1) WO1992013872A1 (fr)
YU (1) YU48892B (fr)
ZA (1) ZA92233B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
DK0678097T3 (da) * 1993-01-08 2000-02-07 Astra Ab Hidtil ukendte colon- eller ileumspecifikke steroidderivater
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE69942578D1 (de) 1998-05-22 2010-08-26 Univ R Bifunktionelle moleküle sowie darauf basierende therapien.
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009607D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medical compositions
HRP20010018A2 (en) 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
GB0110411D0 (en) * 2001-04-27 2001-06-20 Astrazeneca Ab Chemical process
JP2005505578A (ja) * 2001-09-25 2005-02-24 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー ステロイドｃ−２２位アセトニドの立体選択的トランスアセタール化
WO2004005310A2 (fr) 2002-07-08 2004-01-15 Pliva-Istrazivacki Institut D.O.O. Nouveaux composes, compositions et procedes pour traiter les maladies et etats inflammatoires
AU2003264917A1 (en) 2002-07-08 2004-01-23 Pliva - Istrazivacki Institut D.O.O. Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
US20040157810A1 (en) * 2002-08-23 2004-08-12 Teicher Martin H. Corticosteroid conjugates and uses thereof
TW200417371A (en) * 2003-02-21 2004-09-16 Upjohn Co A continuous process for the production of R-rofleponide
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
HRP20030604A2 (en) 2003-07-25 2005-04-30 Pliva-Istra�iva�ki institut d.o.o. Substituted furochromenes, preparation thereof andtheir antiinflammatory action
HRP20030603A2 (en) 2003-07-25 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Substituted furochromene compounds of antiinflammatory action
CN101090908A (zh) 2004-10-27 2007-12-19 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 具有抗炎活性的共轭物
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
WO2008100560A2 (fr) * 2007-02-14 2008-08-21 University Of Southern California Modulateurs de récepteur d'œstrogène, compositions pharmaceutiques associées et procédés d'utilisation
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
MY163048A (en) 2009-05-06 2017-08-15 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3357974A (en) * 1965-12-28 1967-12-12 Merck & Co Inc Processes for preparing 16alpha, 17alpha-acetals and ketals of 16alpha, 17alpha, 21-trihydroxy-delta4-pregnene-3, 20-diones
US3758686A (en) * 1971-12-07 1973-09-11 American Cyanamid Co Method of using steroid acetonides
SE378109B (fr) * 1972-05-19 1975-08-18 Bofors Ab
SE378110B (fr) * 1972-05-19 1975-08-18 Bofors Ab
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
US4749649A (en) * 1983-05-16 1988-06-07 The Upjohn Company Microbial Δ1-dehydrogenation process using a scavenger of toxic oxygen
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
CN1060471A (zh) * 1985-04-04 1992-04-22 得拉科公司 新的16，17-缩醛取代雄甾烷-17β-酮类的制备方法
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
HU203562B (en) * 1989-03-09 1991-08-28 Richter Gedeon Vegyeszet Process for producing new steroide diols and pharmaceutical compositions containing them
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
PL164294B1 (pl) * 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters

Also Published As

Publication number Publication date
CN1058724C (zh) 2000-11-22
SK281801B6 (sk) 2001-08-06
YU6592A (sh) 1995-01-31
EP0570454B1 (fr) 1999-04-07
CN1140178A (zh) 1997-01-15
CN1140059A (zh) 1997-01-15
EP0570454A1 (fr) 1993-11-24
RO111195B1 (ro) 1996-07-30
CN1052155C (zh) 2000-05-10
AP366A (en) 1994-10-21
SI9210065B (en) 2001-12-31
PT100086A (pt) 1994-05-31
HU218275B (en) 2000-07-28
IS3808A (is) 1992-08-05
BG97971A (bg) 1994-04-29
MA22406A1 (fr) 1992-10-01
BG62211B1 (bg) 1999-05-31
ES2133315T3 (es) 1999-09-16
NZ241210A (en) 1993-08-26
US5674861A (en) 1997-10-07
IL100532A (en) 1996-05-14
KR100216720B1 (ko) 1999-10-01
ZA92233B (en) 1992-10-28
EE03111B1 (et) 1998-08-17
FI933450A (fi) 1993-08-03
NO932761D0 (no) 1993-08-02
MX9200324A (es) 1992-09-01
HU9302244D0 (en) 1993-10-28
IS1601B (is) 1996-10-18
IL100532A0 (en) 1992-09-06
SG52557A1 (en) 1998-09-28
RU2111212C1 (ru) 1998-05-20
CN1034868C (zh) 1997-05-14
IE920166A1 (en) 1992-08-12
CZ149693A3 (en) 1994-03-16
AU1230792A (en) 1992-09-07
CN1064079A (zh) 1992-09-02
YU48892B (sh) 2002-10-18
AU661471B2 (en) 1995-07-27
NO304073B1 (no) 1998-10-19
PH31284A (en) 1998-07-06
SE9100341D0 (sv) 1991-02-04
SI9210065A (en) 1995-02-28
ATE178611T1 (de) 1999-04-15
SK79693A3 (en) 1994-03-09
CA2103924A1 (fr) 1992-08-05
NO932761L (no) 1993-08-02
PL170000B1 (pl) 1996-10-31
JPH06505232A (ja) 1994-06-16
DZ1553A1 (fr) 2002-02-17
HUT64973A (en) 1994-03-28
AP9200353A0 (en) 1992-01-31
FI933450A0 (fi) 1993-08-03
PT100086B (pt) 1999-06-30
WO1992013872A1 (fr) 1992-08-20
GR3030657T3 (en) 1999-10-29
DE69228870T2 (de) 1999-08-19
DK0570454T3 (da) 1999-10-18
US5939409A (en) 1999-08-17
DE69228870D1 (de) 1999-05-12
UA41267C2 (uk) 2001-09-17
HK1010733A1 (en) 1999-06-25
CZ281685B6 (cs) 1996-12-11

Similar Documents

Publication Publication Date Title
TNSN92007A1 (fr) Nouveaux steroides
RU93053630A (ru) Новые стероиды, способ их получения, фармацевтический препарат, способ лечения
EP0229654B1 (fr) Traitement des dermatoses inflammatoires et infectieuses diffèrentes de l'acné et de la chute des cheveux
JPH0714869B2 (ja) 抗炎症製薬組成物
AU616188B2 (en) Steroid lotion
TNSN92008A1 (fr) Steroides-esters nouveaux
US5643949A (en) Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use
US5258391A (en) Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use
EP0055029A2 (fr) Préparations pour le traitement de dermatoses
Kaidbey et al. Topical colchicine therapy for recalcitrant psoriasis
CA1109794A (fr) Compose de salicylate anti-inflammatoire
Dobozy et al. Transfusion therapy for erythropoietic protoporphyria
Panja et al. Idiopathic deciduous skin
DZ1324A1 (fr) Dérivés de céphalosporine, procédé pour leur préparation compositions pharmaceutiques les contenant et leur utilisation dans le traitement d'infections bactériennes.
Günther The therapeutic value of retinoic acid in chronic discoid, acute guttate, and erythrodermic psoriasis: clinical observations on twenty‐five patients
ATE18050T1 (de) Triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
DE3027074A1 (de) Benzisoselenazolon enthaltende pharmazeutische praeparate und ihre verwendung
EP0038567B1 (fr) Déazapurine nucléoside, compositions le contenant et son utilisation comme thérapeutique
ES2096203T3 (es) Nuevos derivados de fisostigmina, su uso y formulaciones farmaceuticas que los contienen.
Csato et al. Effect of BN 52021, a platelet activating factor antagonist, on experimental murine contact dermatitis
Pasricha et al. Pluse therapy with dexamethasone in Reiter's disease
JP2522962B2 (ja) 乾癬治療剤
Cardoe et al. Serum concentrations of flurbiprofen in rheumatoid patients receiving large doses of flurbiprofen for long periods
BE901277A (fr) Derives insatures du camphre, leurs procedes de preparation et leur application dans les domaines pharmaceutique et therapeutique.
Bissonnette et al. Drug-induced toxic pustuloderma.